Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALVR

ALVR - AlloVir, Inc. Stock Price, Fair Value and News

0.72USD+0.02 (+2.86%)Delayed as of 21 Feb 2024, 01:56 pm ET
Watchlist

Market Summary

USD0.72+0.02
Delayedas of 21 Feb 2024, 01:56 pm
2.86%

ALVR Stock Price

View Fullscreen

ALVR RSI Chart

ALVR Valuation

Market Cap

79.8M

Price/Earnings (Trailing)

-0.47

EV/EBITDA

0.11

Price/Free Cashflow

-0.64

MarketCap/EBT

-0.45

ALVR Price/Sales (Trailing)

ALVR Profitability

Return on Equity

-86.45%

Return on Assets

-68%

Free Cashflow Yield

-156.91%

ALVR Fundamentals

ALVR Earnings

Earnings (TTM)

-168.9M

Earnings Growth (Yr)

-5.23%

Earnings Growth (Qtr)

2.2%

Breaking Down ALVR Revenue

52 Week Range

0.697.24
(Low)(High)

Last 7 days

-2.8%

Last 30 days

1.5%

Last 90 days

-57.1%

Trailing 12 Months

-88.6%

How does ALVR drawdown profile look like?

ALVR Financial Health

Current Ratio

6.65

ALVR Investor Care

Shares Dilution (1Y)

22.43%

Diluted EPS (TTM)

-1.66

Tracking the Latest Insider Buys and Sells of AlloVir, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 08, 2024
hagen brett r
sold
-7,493
0.6721
-11,150
chief accounting officer
Feb 05, 2024
brainard diana
sold
-27,752
0.67
-41,421
chief executive officer
Feb 05, 2024
sinha vikas
sold
-12,281
0.67
-18,331
see remarks
Feb 05, 2024
miller edward
sold
-5,942
0.67
-8,869
general counsel
Feb 05, 2024
hagen brett r
sold
-3,880
0.67
-5,792
chief accounting officer
Jan 23, 2024
miller edward
sold
-873
0.6708
-1,302
general counsel
Jan 23, 2024
hagen brett r
sold
-604
0.6708
-901
chief accounting officer
Jan 23, 2024
brainard diana
sold
-6,368
0.6704
-9,500
chief executive officer
Jan 23, 2024
sinha vikas
sold
-2,149
0.6708
-3,205
see remarks
Jan 04, 2024
miller edward
sold
-270
0.639
-424
general counsel

1–10 of 50

Which funds bought or sold ALVR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-63,000
30,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
142,000
142,000
0.01%
Feb 15, 2024
Legal & General Group Plc
reduced
-82.44
-73,639
4,329
-%
Feb 15, 2024
BARCLAYS PLC
added
274
8,000
47,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
31.73
-60,686
43,322
-%
Feb 14, 2024
UBS OCONNOR LLC
sold off
-100
-494,500
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
6.8
-3,918,120
1,997,660
-%
Feb 14, 2024
Ameritas Investment Partners, Inc.
unchanged
-
-3,540
1,637
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
163,063
163,063
-%

1–10 of 47

Are Funds Buying or Selling ALVR?

Are funds buying ALVR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALVR
No. of Funds

Unveiling AlloVir, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
gilead sciences, inc.
14.6%
16,635,286
SC 13G/A
Feb 09, 2024
artal international s.c.a.
5.8%
6,597,167
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 01, 2024
ecor1 capital, llc
9.3%
10,655,366
SC 13G
Jan 09, 2024
wilson john robert
4.69%
5,355,877
SC 13G/A
Jan 09, 2024
wilson john robert
8.98%
5,562,954
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G/A

Recent SEC filings of AlloVir, Inc.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 15, 2024
RW
RW
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
8-K
Current Report
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to AlloVir, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AlloVir, Inc. News

Latest updates
GlobeNewswire111 minutes ago
Yahoo Finance29 Jan 202408:00 am
InvestorsObserver25 Jan 202408:00 am

AlloVir, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-12.2%248283244277294200231287317328351371394118129139
  Current Assets-13.0%220253212243272177206253282316340361384107-127
    Cash Equivalents-51.4%96.0019711610612471.0010020224322516912314278.0016961.00
  Net PPE-11.3%1.001.001.001.001.001.001.002.001.001.001.001.000.000.00-0.00
Liabilities-1.1%53.0054.0051.0053.0040.0042.0039.0061.0049.0025.0021.0018.0020.0016.0017.0018.00
  Current Liabilities8.2%33.0031.0025.0024.0021.0022.0019.0038.0024.0021.0016.0012.0014.009.00-9.00
Shareholder's Equity-14.7%1952291942252531581922252673023303533745.004.004.00
  Retained Earnings-8.0%-596-552-507-465-427-385-385-297-239-193-156-125-99.90-76.29--55.32
  Additional Paid-In Capital1.3%7927827016916815445335225074964864784745.00-4.00
Shares Outstanding0.2%11411493.0093.0085.0064.0064.0064.0063.0062.0062.0062.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-27.1%-34,476-27,122-32,118-31,571-35,127-28,878-46,476-28,068-36,437-22,888-18,926-21,093-18,057-11,118-10,543---
  Share Based Compensation1.7%10,46810,28810,0299,04210,85510,95110,46715,86010,2869,7268,1034,4313,860492646---
Cashflow From Investing-276.4%-66,85137,89441,72413,537-38,557-479-54,979-13,52354,96779,71264,8271,922-210,26325,00513,839---
Cashflow From Financing----292126,425--65.00----354------

ALVR Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 34,156$ 30,004$ 99,698$ 90,450
General and administrative12,80512,94637,79740,318
Total operating expenses46,96142,950137,495130,768
Loss from operations(46,961)(42,950)(137,495)(130,768)
Total other income (loss), net:    
Interest income1,5226684,362978
Other income (loss), net1,1672102,411(634)
Loss before income taxes(44,272)(42,072)(130,722)(130,424)
Income tax expense000150
Net loss$ (44,272)$ (42,072)$ (130,722)$ (130,574)
Net loss per share - basic$ (0.39)$ (0.5)$ (1.3)$ (1.83)
Net loss per share - diluted$ (0.39)$ (0.5)$ (1.3)$ (1.83)
Weighted-average common shares outstanding - basic113,894,18884,948,837100,683,32271,213,219
Weighted-average common shares outstanding - diluted113,894,18884,948,837100,683,32271,213,219
Comprehensive loss:    
Net loss$ (44,272)$ (42,072)$ (130,722)$ (130,574)
Other comprehensive income (loss), net of tax:    
Unrealized gain (loss) on available-for-sale securities25(119)268(408)
Total other comprehensive income (loss)25(119)268(408)
Comprehensive loss$ (44,247)$ (42,191)$ (130,454)$ (130,982)

ALVR Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 95,627$ 106,092
Short-term investments117,691127,703
Interest receivable234157
Prepaid expenses and other current assets5,8927,100
Prepaid expenses to related party5752,000
Total current assets220,019243,052
Restricted cash852852
Other assets1,425612
Property and equipment, net673930
Operating lease right-of-use assets25,34331,633
Total assets248,312277,079
Current liabilities:  
Accounts payable3,9253,004
Accrued expenses15,92413,985
Income tax payable0128
Operating lease liability, current12,9767,165
Total current liabilities33,06624,338
Operating lease liability, long term19,91228,222
Total liabilities52,97852,560
Stockholders’ equity:  
Preferred stock, $0.0001 par value: 10,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value: 300,000,000 and 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 113,972,541 and 93,268,069 shares issued at September 30, 2023 and December 31, 2022, respectively; and 113,966,594 and 93,093,243 shares outstanding at September 30, 2023 and December 31, 2022, respectively119
Additional paid-in capital792,020690,753
Accumulated other comprehensive loss(200)(468)
Accumulated deficit(596,497)(465,775)
Total stockholders’ equity195,334224,519
Total liabilities and stockholders’ equity248,312277,079
Related Party  
Current liabilities:  
Amount due to related party$ 241$ 56
ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
 CEO
 WEBSITEwww.allovir.com
 EMPLOYEES113

AlloVir, Inc. Frequently Asked Questions


What is the ticker symbol for AlloVir, Inc.? What does ALVR stand for in stocks?

ALVR is the stock ticker symbol of AlloVir, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AlloVir, Inc. (ALVR)?

As of Tue Feb 20 2024, market cap of AlloVir, Inc. is 79.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALVR stock?

You can check ALVR's fair value in chart for subscribers.

What is the fair value of ALVR stock?

You can check ALVR's fair value in chart for subscribers. The fair value of AlloVir, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AlloVir, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALVR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AlloVir, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALVR is over valued or under valued. Whether AlloVir, Inc. is cheap or expensive depends on the assumptions which impact AlloVir, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALVR.